LEXICON PHARMACEUTICALS INC (LXRX)

US5288723027 - Common Stock

2.54  +0.17 (+7.17%)

After market: 2.5 -0.04 (-1.57%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to LXRX. LXRX was compared to 599 industry peers in the Biotechnology industry. LXRX has a bad profitability rating. Also its financial health evaluation is rather negative. LXRX is quite expensive at the moment. It does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

LXRX had negative earnings in the past year.
LXRX had a negative operating cash flow in the past year.
LXRX had negative earnings in 4 of the past 5 years.
In the past 5 years LXRX reported 4 times negative operating cash flow.

1.2 Ratios

LXRX has a Return On Assets (-57.07%) which is in line with its industry peers.
The Return On Equity of LXRX (-113.12%) is worse than 60.14% of its industry peers.
Industry RankSector Rank
ROA -57.07%
ROE -113.12%
ROIC N/A
ROA(3y)-48.44%
ROA(5y)-31.32%
ROE(3y)-67.26%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

LXRX has a Gross Margin of 20.00%. This is in the better half of the industry: LXRX outperforms 74.83% of its industry peers.
LXRX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for LXRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.34%
GM growth 5Y0.42%

3

2. Health

2.1 Basic Checks

LXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LXRX has more shares outstanding
Compared to 5 years ago, LXRX has more shares outstanding
The debt/assets ratio for LXRX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -7.18, we must say that LXRX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -7.18, LXRX is doing worse than 74.49% of the companies in the same industry.
LXRX has a Debt/Equity ratio of 0.71. This is a neutral value indicating LXRX is somewhat dependend on debt financing.
LXRX's Debt to Equity ratio of 0.71 is on the low side compared to the rest of the industry. LXRX is outperformed by 77.87% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Altman-Z -7.18
ROIC/WACCN/A
WACC11.06%

2.3 Liquidity

A Current Ratio of 6.92 indicates that LXRX has no problem at all paying its short term obligations.
LXRX has a better Current ratio (6.92) than 63.85% of its industry peers.
LXRX has a Quick Ratio of 6.91. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
LXRX has a Quick ratio of 6.91. This is in the better half of the industry: LXRX outperforms 64.19% of its industry peers.
Industry RankSector Rank
Current Ratio 6.92
Quick Ratio 6.91

4

3. Growth

3.1 Past

LXRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -22.58%.
LXRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -66.67%.
The Revenue for LXRX have been decreasing by -74.44% on average. This is quite bad
EPS 1Y (TTM)-22.58%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-61.54%
Revenue 1Y (TTM)-66.67%
Revenue growth 3Y-93.23%
Revenue growth 5Y-74.44%
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 27.77% on average over the next years. This is a very strong growth
Based on estimates for the next years, LXRX will show a very strong growth in Revenue. The Revenue will grow by 377.60% on average per year.
EPS Next Y-31.47%
EPS Next 2Y-10.14%
EPS Next 3Y2.4%
EPS Next 5Y27.77%
Revenue Next Year2597.87%
Revenue Next 2Y1705.11%
Revenue Next 3Y787.73%
Revenue Next 5Y377.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LXRX. In the last year negative earnings were reported.
Also next year LXRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.14%
EPS Next 3Y2.4%

0

5. Dividend

5.1 Amount

LXRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

LEXICON PHARMACEUTICALS INC

NASDAQ:LXRX (2/23/2024, 7:00:00 PM)

After market: 2.5 -0.04 (-1.57%)

2.54

+0.17 (+7.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap619.81M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -57.07%
ROE -113.12%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 20%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 6.92
Quick Ratio 6.91
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-22.58%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-31.47%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-66.67%
Revenue growth 3Y-93.23%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y